Asarina Pharma AB (publ) Annual Report 2020 released
Asarina Pharma CEO Peter Nordkild: “2020 and early 2021 have seen new research and additional data confirming and consolidating the efficacy and potential of our flagship compound Sepranolone. As we continue forward into an eventful 2021, we remain confident of the significant clinical relevance of Allopregnanolone, and the ability of our flagship compound Sepranolone to suppress Allopregnanolone’s negative, often devastating effects.”FINANCIAL HIGHLIGHTS · R&D expenses remained at 2019 level reflecting strict cost control · Staff costs declined following headcount reduction ·